Introduction
The erbB family of type I receptor tyrosine kinases (erbB1 or the epidermal growth factor receptor-EGFR, erbB2, erbB3, and erbB4) are widely expressed in epithelial, mesenchymal, and neuronal tissues where they play a pivotal role in regulating cell proliferation, survival, and differentiation (Sibilia and Wagner, 1995; Threadgill et al., 1995) . Overexpression of wild-type erbB2 or EGFR, or expression of constitutively activated receptor mutants, transforms cells in vitro (Di Fiore et al., 1987; DiMarco et al., 1989; Hudziak et al., 1987; Qian et al., 1995) , and correlates with a poorer clinical outcome in some breast cancers and a variety of other malignancies (Slamon et al., 1987 (Slamon et al., , 1989 Bacus et al., 1994) . Consequently, considerable attention has focused on developing therapeutically active monoclonal antibodies (mAb) or small molecule kinase inhibitors that target either receptor.
A family of peptide ligands regulates erbB receptor signaling, and includes epidermal growth factor (EGF) and transforming growth factor a (TGF-a) which both bind to EGFR (Reise and Stern, 1998; Salomon et al., 1995) . Ligand binding induces erbB receptor homoand heterodimerization, which in turn leads to receptor autophosphorylation and activation. ErbB2 is the preferred heterodimeric partner for EGFR, erbB3, and erbB4 (Graus-Porta et al., 1997; Tzahar et al., 1996) . Although a number of soluble ligands have been identified for these three receptors, none has been identified for erbB2, which seems to be transactivated following heterodimerization (Ullrich and Schlessinger, 1990; Wada et al., 1990; Karunagaran et al., 1996; Stern and Kamps, 1988) .
With the exception of erbB3, all erbB receptor family members share a highly conserved cytoplasmic tyrosine kinase domain. Autophosphorylation of specific cytoplasmic tyrosine residues establishes binding sites for Src-homology 2 (SH2) and phosphotyrosine-bindingdomain containing proteins that in turn link to downstream effectors involved in cell proliferation (mitogen-activated protein kinases or MAPK; also known as Erk1/2) and survival (phosphatidylinositol 3-kinase/AKT) pathways (Olayioye et al., 1998; Luttrell et al., 1994; Levkowitz et al., 1996; Klapper et al., 2000; Egan and Weinberg, 1993; Kavanaugh and Williams, 1994; Daly, 1999) .
Much attention has focused on the significance of EGFR or erbB2 overexpression in tumor physiology. However, increased expression of EGF or TGF-a is a poor prognostic indicator in some cancer patients (Grandis et al., 1998; Albanell et al., 2001) , and locally increased concentrations of EGF or other ligands in the tumor microenvironment appear to be responsible for maintaining heterodimers in an activated state even in the absence of receptor overexpression (Albanell et al., 2001; Howell et al., 1998; Jiang et al., 1998) . Thus, it is important to develop therapeutic strategies that are not solely dependent upon receptor overexpression for their anti-tumor activity.
Herceptin, a humanized anti-erbB2 monoclonal antibody has been approved for the treatment of the minority of breast cancers that either overexpress erbB2 or demonstrate erbB2 gene amplification (Cobleigh et al., 1999) . Similarly, several anti-EGFR targeted approaches are currently being investigated in the clinic including C225, a human-mouse chimeric anti-EGFR mAb (Goldstein et al., 1995; Levitzki and Gazit, 1995; Mendelsohn, 1997) . Because erbB2-containing heterodimers elicit such potent mitogenic signals, interrupting both erbB2 and EGFR simultaneously is an appealing therapeutic strategy (Earp et al., 1995) . Recently, the combination of Herceptin and C225 was shown to exhibit enhanced growth inhibition in OVCA 420 human ovarian carcinoma cells compared with either mAb alone (Ye et al., 1999) . However, EGF and C225 have comparable binding affinities for EGFR, and EGF was able to reverse the growth inhibitory effects of combination Herceptin and C225. This approach may therefore be problematic in the clinic, where patients may already have increased levels of EGF receptor ligands (Ye et al., 1999) .
To circumvent this dilemma, a number of small molecule, dual EGFR-erbB2 tyrosine kinase inhibitors have recently been identified and their pre-clinical antitumor activities reported (Fry et al., 1998; Cockerill et al., 2001; Rusnak et al., 2001a,b) . We now report that GW572016, a reversible, dual tyrosine kinase inhibitor of both EGFR and erbB2, inhibits not only baseline activation of both receptors, but also interrupts downstream activation of Erk1/2 MAP kinases and AKT. Although erbB inhibitors have been largely associated with reversible growth inhibition (cytostasis), AKT inhibition in GW572016 treated erbB2-expressing cells was associated with significant apoptosis. We show that GW572016 inhibits signal transduction in EGF-stimulated tumor lines that do not overexpress EGFR, which has implications in the clinic where EGFR ligands appear to mediate tumor progression despite the absence of EGFR overexpression. Importantly, exogenous EGF did not reverse the anti-tumor effects of GW572016.
To our knowledge, our study is one of the first in which the in vivo effects of an erbB inhibitor were examined in the same tumor implant biopsied before and after treatment in an attempt to minimize interanimal variability in baseline expression of activated EGFR and erbB2. GW572016 inhibits tumor xenograft growth (Rusnak et al., 2001b) . Here we elucidate its mechanism of action by demonstrating that GW572016 inhibits the activation of proliferation and survival pathways in both erbB2 and EGFR-dependent tumors. Our data indicate that GW572016 is a potent dual inhibitor of EGFR and erbB2, leading to tumor growth arrest and/or apoptosis even in the presence of saturating concentrations of EGF, thus supporting its use in the clinic.
Results

GW572016 inhibits erbB2 tyrosine phosphorylation and downstream activation of Erk1/2
We examined the effects of GW572016 on the activation-state of erbB2 and EGFR, as well as downstream proliferation and survival pathways using S1 cells, which express high levels of phosphorylated erbB2. S1 cells were established by single cell cloning of Hb4ac5.2 cells, a mammary epithelial line stably transfected with erbB2 (Harris et al., 1999) . GW572016 inhibition of erbB2 tyrosine phosphorylation (i.e. formation of p-Tyr/erbB2) was dosedependent. Partial inhibition was seen at 500 nM, with complete inhibition at 2.5 mM after 72 h (Figure 1 ).
ErbB2 overexpression is associated with the activation of downstream pathways involved in the propagation of proliferative signals such as Erk1/2 MAP kinases (Janes et al., 1994) . After 72 h exposure, GW572016 inhibited activated, phosphorylated Erk1/2 (p-Erk) by more than 50% at 500 nM and 2.5 mM, with 100% inhibition at 5 mM compared to vehicle treated controls (Figure 1 ). Total steady state Erk protein remained unchanged. A similar dose-dependent relationship was observed in HN5 cells, a squamous cell head and neck carcinoma line that overexpresses EGFR (data not shown).
GW572016 blocks EGF-induced activation of Erk1/2 and AKT in both erbB2 and EGFR overexpressing carcinoma cells EGF was recently shown to reverse growth inhibition of OVCA 420 ovarian carcinoma cells treated with combination Herceptin and C225, mAbs targeting Figure 1 Inhibition of activated erbB2 receptor and ERK1/2 MAP kinases by GW572016 in an erbB2 overexpressing mammary epithelial cell line. Activated erbB2 (p-Tyr/erbB2), activated Erk1/2 (p-Erk1/2), and total Erk1/2 were assessed by Western blot in S1 cells treated with GW572016 at the indicated concentrations (mM) for 72 h. Controls were treated with vehicle alone (V), DMSO at a final concentration of 0.1% erbB2 and EGFR, respectively (Ye et al., 1999) . The authors concluded that dual inhibition of EGFR and erbB2 would result in more effective anti-tumor activity. Since EGF levels have been shown to be elevated in cancer patients (Grandis et al., 1998; Albanell et al., 2001) , we next examined whether EGF would reverse GW572016 inhibition of activated EGFR, erbB2, and downstream effector molecules. BT474 is an erbB2 overexpressing breast carcinoma line that also expresses EGFR, albeit at lower levels. BT474 cells constitutively express activated erbB2 (pTyr/erbB2) ( Figure 2a ). EGF stimulation did not significantly increase steady state levels of p-Tyr/erbB2, consistent with this receptor being maximally activated in these cells at baseline (Lane et al., 2000) . Although EGFR is constitutively expressed at only low levels in BT474 cells, stimulation with EGF increased p-Erk1/2 levels indicating that EGFR signaling was functional. Exposure to 1 mM GW572016 for 24 h inhibited EGF stimulation of p-Erk1/2 ( Figure 2a ). GW572016 also inhibited baseline levels of p-Tyr/erbB2, an effect not reversed by EGF.
ErbB2 signaling also activates the PI3K/AKT pathway, which plays an important role in regulating cell survival (Daly, 1999) . Constitutive activation of AKT has been implicated in tumor resistance to chemotherapeutic agents (Thakkar et al., 2001; Tenzer et al., 2001; Brognard et al., 2001) . Stimulation of BT474 cells with EGF increased levels of activated, phosphorylated AKT (p-AKT, Ser 473) approximately twofold over baseline ( Figure 2a ). In contrast, GW572016 treatment completely inhibited p-AKT. Exogenous EGF did not reverse inhibition.
The effects of GW572016 were examined in HN5 carcinoma cells, which overexpress EGFR (Figure 2b ). EGFR phosphorylation increased in response to 50 ng/ ml EGF. Treating cells with 5 mM GW572016 not only inhibited baseline levels of p-Tyr/EGFR, but also blocked the stimulatory effect of EGF on p-Tyr/ EGFR. As in erbB2 overexpressing cells, GW572016 treatment also inhibited downstream p-Erk1/2 in HN5 cells. Simultaneous administration of EGF did not reverse these inhibitory effects. Although GW572016 treatment inhibited p-AKT in HN5 cells, the effect was smaller than in erbB2-overexpressing tumor cells.
ErbB2 overexpressing cells undergo apoptosis in response to GW572016
The effects of GW572016 on cell survival were assessed in exponentially growing S1 cells (Figure 3 ). The sub-G1 apoptotic fraction comprised 2% of vehicle-treated S1 cells. The percentage of apoptotic cells increased 23-fold to 46% after 72 h exposure to GW572016, with a concomitant reduction in the percentage of cells in S phase and G2/M. A similar result was observed in BT474 cells (Rusnak et al., 2001b) . Although growth arrested, we did not see significant apoptosis of GW572016 treated HN5 cells (data not shown), consistent with previous observations (Rusnak et al., 2001b) .
The effects of GW572016 on Erk1/2 activation state differ from that of Herceptin Herceptin, a humanized anti-erbB2 mAb, exhibits activity in the clinic against breast cancers that either overexpress erbB2 protein or demonstrate erbB2 gene amplification (Cobleigh et al., 1999) . However, the Figure 2 The effects of EGF and GW572016 on the activation state of erbB2, EGFR and downstream Erk1/2 and AKT in erbB2 and EGFR overexpressing tumor cell lines. ErbB2 overexpressing BT474 cells (a) and EGFR overexpressing HN5 cells (b) were cultured in the presence or absence of GW572016 (1 mM for BT474; 5 mM for HN5) in serum-free medium for 24 h. EGF (50 ng/ml) was added to cell cultures as indicated. Equal amounts of protein were used to assess activated erbB2 (p-Tyr/erbB2) in BT474 cells, activated EGFR (p-Tyr/EGFR) in HN5 cells and Erk1/2, p-Erk1/2, AKT, p-AKT by Western blot, as described in Materials and methods Inhibition of tumor growth and survival pathways by GW572016 W Xia et al exact mechanism by which Herceptin exerts its antitumor activity is unclear. We compared the effects of GW572016 with Herceptin on p-Erk1/2 in both BT474 and HN5 cells (Figure 4 ), using treatment conditions for Herceptin previously shown to inhibit the growth of erbB2 overexpressing cells (Lane et al., 2000) . At 72 h, Herceptin had very little effect on p-Erk1/2 levels compared with untreated controls in either cell line, while GW572016 at 500 nM or 1 mM inhibited p-Erk1/2 in both BT474 and HN5 cells. Neither Herceptin nor GW572016 reduced total Erk1/2 steady state protein levels.
GW572016 and Herceptin elicit differential effects on the activation state of erbB2, EGFR and downstream Erk 1/2 in cells expressing low levels of erbB2 and EGFR
Hb4a is a mammary epithelial line that expresses low levels of both erbB2 and EGFR (Harris et al., 1999) . Steady state p-Tyr/EGFR levels increased in response to EGF stimulation ( Figure 5 ) indicated the integrity of the EGFR pathway. GW572016 not only reduced baseline p-Tyr/EGFR levels in Hb4a cells but also blocked the stimulatory effects of EGF on EGFR tyrosine phosphorylation ( Figure 5 ). Similarly, GW572016 reduced the baseline amount of p-Tyr/ erbB2 and p-Erk, effects not reversed by EGF. After 72 h exposure to Herceptin, there was relatively little change in baseline levels of p-Tyr/erbB2 or p-Erk levels, while total erbB2 steady state protein was reduced ( Figure 5 ). Concurrent treatment with GW572016 and Herceptin did not reduce levels of pTyr/erbB2 or p-Erk below those observed following treatment with GW572016 alone.
EGF stimulated Hb4a cell growth by 20% over vehicle treated controls (Figure 6 ), while treatment with GW572016 (2.5 mM) inhibited cell growth 50% compared with vehicle treated controls. Importantly, EGF did not reverse GW572016 induced growth inhibition.
In vivo inhibitory effects of GW572016 on receptor p-Tyr expression and downstream signaling components
The effects of GW572016 on the activation of EGFR and downstream pathways were examined in the HN5 human tumor xenograft. To simulate the clinical setting where each patient serves as his or her own control, we conducted experiments whereby each animal served as its own control, taking biopsies from the same tumor implant before and after treatment with GW572016. As shown in Figure 7a , GW572016 treatment resulted in a dose-response effect, with very Figure 3 GW572016-induced apoptosis of an erbB2 overexpressing mammary epithelial cell line. S1 cells in exponential log growth phase were treated with GW572016 (5 mM), vehicle (0.1% DMSO), or were untreated controls. After 72 h, cell cycle analysis was performed using propidium iodide staining and flow cytometry as described in Materials and methods. The percentage of cells in G1, S phase, and G2/M are indicated. The sub-G1 peak represents the apoptotic fraction Figure 4 Comparison of the effects of GW572016 with Herceptin on the expression of activated Erk1/2 in BT474 and HN5 cell lines. Exponentially growing BT474 and HN5 cells were cultured with either GW572016 or Herceptin at the indicated concentrations for 72 h. Cell lysates were prepared and total Erk1/2 and activated Erk1/2 (p-Erk1/2) were assessed by Western blot little inhibition of p-Tyr/EGFR at 10 mg/kg, increasing at 30 and 100 mg/kg. One of the post-therapy biopsies was not evaluable at each of the two higher doses, as the samples contained inadequate EGFR protein.
We next examined the effects of GW572016 treatment on Erk and AKT. There was little effect in animals treated with vehicle alone or administered 10 mg/kg GW572016 (data not shown). However, at 30 mg/kg/dose, GW572016 inhibited p-Erk1/2 and p-AKT in tumors without affecting total steady state protein levels of either molecule (Figure 7b ). Treatment at 100 mg/kg/dose showed similar inhibition of p-Erk and p-AKT (data not shown).
To highlight the dual inhibitory nature of GW572016, we next examined the effects of GW572016 on the activation state of erbB2 and Erk1/2 in BT474 xenografts. In contrast to HN5, BT474 tumor implants were not amenable to re-biopsy. Mice with established s.c. tumors were administered either vehicle alone or GW572016 at 100 mg/kg twice daily by oral gavage for five doses. Both p-Tyr/erbB2 Figure 5 Comparison of the effects of GW572016 and Herceptin on the activation state of erbB2, EGFR and downstream Erk1/2 in Hb4a cells. Exponentially growing Hb4a cells were treated with either 2.5 mM GW572016 or Herceptin (10 mg/ml) for 72 h and stimulated with EGF (50 ng/ml) for 15 min as described in Materials and methods. Steady state levels of activated erbB2 and EGFR (p-Tyr/ErbB2 and p-Tyr/EGFR); total erbB2 and EGFR; activated Erk1/2 (p-Erk1/2) and total Erk1/2 were assessed by either IP Western or Western blot (see Materials and methods) Figure 6 The effect of EGF on GW572016-induced growth arrest in Hb4a cells. Exponentially growing Hb4a cells were cultured in 35-mm petri dishes with serum-free medium containing 1.5% BSA. Treatment conditions include: DMSO (final concentration of 0.1%) as the vehicle control; EGF (50 ng/ml); GW572016 (2.5 mM); concurrent GW572016 (2.5 mM)+EGF (50 ng/ml). Viable cells were counted after 72 h using trypan blue exclusion. These data are representative of three independent experiments Figure 7 GW572016 inhibition of activated EGFR and downstream Erk1/2 and AKT in HN5 xenografts. HN5 tumor xenografts were established s.c. in CD-1 nude mice as described in Materials and methods. When tumors were palpable, treatment with GW572016 was initiated at the indicated doses; controls were treated with vehicle alone. Vehicle or GW572016 was administered by oral gavage twice daily at a 6 h interval, for five doses. The same tumor implant was biopsied before (Pre) and after the fifth dose of GW572016 (Post). Each treatment cohort comprised three animals (indicated as 1, 2, and 3). (a) Activated receptor (pTyr/EGFR) was assessed by IP Western blot and total EGFR steady state protein (EGFR) by Western blot. (b) Total Erk1/2 and AKT, activated Erk1/2 (p-Erk1/2) and AKT (p-AKT) were assessed by Western blot loading equal amounts of protein from tumor biopsies in mice treated with 30 mg/kg GW572016 and p-Erk1/2 were inhibited by GW572016 without affects on total erbB2 or Erk1/2 steady state protein levels (Figure 8 ).
Discussion
GW572016 is a potent reversible, dual inhibitor of the tyrosine kinase domains of both EGFR and erbB2, with IC 50 values against purified EGFR and erbB2 of 10.2 and 9.8 nM, respectively (Rusnak et al., 2001b) . Recent reports have demonstrated that GW572016 inhibits EGFR or erbB2 autophosphorylation in tumor cell lines that overexpress either receptor (Rusnak et al., 2001b) , an effect that was primarily associated with tumor cell growth arrest. In the current study, we investigated the effect of GW572016 on downstream survival and proliferation pathways to help elucidate its mechanism of action. We also studied whether or not EGF could reverse these effects. Identifying a panel of downstream effector molecules would be useful in the clinical development of GW572016, by helping to (i) identify in which clinical settings and patients populations GW572016 would be most effective, and (ii) identify a biologically effective dose, in place of the traditional method based on maximally tolerated dose as used for conventional cytotoxics.
Most mitogenic signals transduced through growth factor receptor activation ultimately converge on a common downstream effector, Erk1/2 MAP kinase (Egan and Weinberg, 1993) . Activated Erk1/2 serves as a transcription factor regulating tumor cell proliferation and survival (Pulverer et al., 1991) . Increased expression of activated Erk1/2 has been demonstrated in a number of human malignancies (Hoshino et al., 1999; Albanell et al., 2001) , and overexpression of erbB2 in tumor cell lines results in the upregulation of activated Erk1/2 (Janes et al., 1994) . Our data show that GW572016 inhibits baseline Erk1/2 activation in both EGFR and erbB2-dependent tumor lines. Furthermore, although EGF stimulated the expression of activated p-Erk1/2 in BT474 cells (which express relatively low levels of EGFR), GW572016 completely inhibited these effects. These results highlight the importance of ligand-induced growth effects regardless of the levels of receptor expression. They also show that Erk1/2 may be a useful downstream biomarker correlating with the ability of GW572016 to inhibit tumor progression.
Erk1/2 may not be a useful biomarker for all erbB-targeted therapies. In contrast to GW572016, Herceptin did not inhibit Erk1/2 activation in two different erbB2 overexpressing cell lines. Herceptin did inhibit erbB2 phosphorylation, although less than GW572016. Despite its antiproliferative effects in tumor cell lines, there have been contradictory reports on the effects of Herceptin on erbB2 phosphorylation state as well as downstream effectors such as Erk1/2 MAP kinases (Ye et al., 1999; Lane et al., 2000; Scott et al., 1991) . Differences in cell lines or the time point at which p-Erk1/2 was examined may explain these discrepancies.
The PI-3 kinase/AKT pathway is involved in protecting cells from apoptosis. In many tumors, constitutive activation of AKT has been implicated as a mechanism of resistance to cytotoxic chemotherapies (Thakkar et al., 2001; Tenzer et al., 2001; Brognard et al., 2001) . Strategies designed to inhibit AKT activation could work by inducing tumor cell apoptosis by themselves, or by sensitizing tumors to the cytotoxic effects of concurrent chemotherapy. Here we show that GW572016 inhibits baseline phosphorylation of AKT in erbB2 (S1) and EGFR (HN5) dependent tumor lines, an effect which was not reversed by the presence of EGF. The ability of GW572016 to potently inhibit p-AKT was associated with a 23-fold increase in the percentage of S1 cells undergoing apoptosis compared to vehicle treated controls. In contrast, apoptosis increased only slightly in HN5 cells (Rusnak et al., 2001b) . These findings are consistent with recent reports indicating that the PI-3 kinase/AKT pathway appears to be more dependent upon erbB2 signaling than EGFR (Tari and Lopez-Berestein, 2000) . Since p-AKT inhibition was more pronounced in erbB2 overexpressing cells, induction of apoptosis might in part be dependent upon the degree to which p-AKT is inhibited. Whether or not GW572016 alone induces apoptosis, its ability to inhibit p-AKT indicates that it may synergize with cytotoxic agents or radiotherapy in inducing tumor cell death.
Our results in vitro were replicated in human tumor xenografts. We attempted to minimize inter-animal baseline differences in the levels of activated EGFR, Erk1/2 and AKT by biopsying the same HN5 tumor implant before and after treatment. This approach most closely mimics the clinical setting where each Figure 8 GW572016 inhibition of ErbB-2 and downstream Erk1/ 2 activation in BT474 xenografts. BT474 tumor xenografts were established as described in Materials and methods. When tumors were palpable, GW572016 was administered by oral gavage twice daily at 6 h intervals, for five doses. Controls were treated with vehicle alone. The tumor implant was removed after the fifth dose of GW572016. Each treatment cohort comprised three animals: vehicle (lanes 1, 2 and 3) and GW572016 (lanes 4, 5 and 6). Activated receptor (p-Tyr/ErbB-2) was assessed by IP Western blot and total ErbB-2 steady state protein (ErbB-2), total Erk1/2 and activated Erk1/2 (p-Erk1/2) were assessed by Western blot loading equal amounts of protein from tumor biopsies patient serves as his or her own control. GW572016 inhibited receptor autophosphorylation, as well as downstream p-Erk1/2 and p-AKT in tumor implants. The dual inhibitory nature of GW572016 was demonstrated in BT474 xenografts where GW572016 inhibited activated erbB2 as well as downstream pErk1/2. The effects of GW572016 on activated erbB2 and EGFR, as well as the activation of downstream intermediaries correlate with previously reported growth inhibition of both BT474 and HN5 xenografts at the doses of GW572016 administered in the current study (Rusnak et al., 2001b) .
These data provide strong support for the use of GW572016 in a variety of tumors either overexpressing EGFR or erbB2, or with evidence of constitutively activated EGFR or erbB2. The effect of GW572016 on survival pathways provides pre-clinical scientific support for combining this compound with cytoreductive therapies.
The inability of EGF to reverse the anti-tumor effects of GW572016 at a molecular level and on the proliferation of cells in vitro cannot be understated. Some tumors may not quantitatively overexpress either erbB2 or EGFR, while remaining dependent upon these receptors for growth and survival signals.
Even low levels of EGFR may be activated in the presence of ligands such as EGF, followed by formation of EGFR/erbB2 heterodimers and erbB2 transactivation. GW572016 offers the distinct clinical advantage of a potent, reversible dual inhibitor of both erbB2 and EGFR whose effects on pathways involved in regulating tumor progression and survival are not reversed in the presence of EGF.
Materials and methods
Materials
The erbB2 overexpressing human breast adenocarcinoma cell line, BT474, was obtained from the American Type Culture Collection (Rockville, MD, USA). The HB4a cell line is derived from human mammary luminal tissue, and erbB2 transfection of HB4a yielded the cell line HB4a C5.2 (Harris et al., 1999) . The S1 cell line was established by sub-cloning HB4a C5.2, and was chosen for further studies as it expressed high levels of phosphorylated erbB2 protein. The EGFR overexpressing LICR-LON-HN5 head and neck carcinoma cell line, HN5, was kindly provided by Helmout Modjtahedi at the Institute of Cancer Research, Surrey, UK. EGF was purchased from Sigma Chemical (St. Louis, MO, USA). Anti-phosphotyrosine antibody was purchased from Sigma Chemical. Anti-EGFR (Ab-12) and anti-c-erbB2 (Ab-11) antibodies were from Neo Markers (Union City, CA, USA). Anti-phospho-AKT (Ser437) was from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-AKT1/2, antiphospho-Erk1/2, anti-Erk1 and anti-Erk2 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Herceptin was purchased from Genentech, Inc. (South San Francisco, CA, USA). SuperSignal West Femto Maximum Sensitivity Substrate was from Pierce (Rockford, IL, USA). Protein G agarose was purchased from Boehringer Mannheim (Germany). GW572016, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, was synthesized as previously described (Cockerill et al., 2001) . GW572016 for cell culture work was dissolved in DMSO.
Cell cultures
HN5 cells were cultured in DMEM supplemented with high glucose and 10% fetal bovine serum (FBS). HB4a cells grew in RPMI 1640 supplemented with L-glutamine, 10% FBS (Hyclone), 10 mg/ml hydrocortisone, and 5 m/ml insulin. BT474 cells were cultured under identical conditions to HB4a, but without hydrocortisone. S1 cells were cultured in RPMI 1640 supplemented with L-glutamine, 10% FBS and 50 mg/ml hygromycin. Cell cultures were maintained in a humidified atmosphere of 5% CO 2 at 378C.
EGF stimulation experiments
Cells were seeded at low density in serum free-medium supplemented with 1.5% BSA, and then exposed for 24 h to GW572016 at various concentrations as indicated in the figure legends, or 10 mg/ml Herceptin. Cells were stimulated with 50 ng/ml EGF for 15 min, harvested on ice, and then lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.25% (w/v) deoxycholate, 1% NP-40, 5 mM sodium orthovanadate, 2 mM sodium fluoride, and a protease inhibitor cocktail).
Cell cycle analysis
Cells were harvested and fixed with 70% ethanol in PBS. Cell pellets were then resuspended in 0.5 ml PBS containing propidium iodide (50 mg/ml) and DNase-free RNase (100 mg/ ml). Cell cycle analysis was performed using a BD Flow Cytometer (Becton Dickinson, San Jose, CA, USA).
Immunoprecipitation and Western blots
Whole cell extracts were prepared by scraping cells off petri dishes, washing the cell pellet twice in phosphate buffered saline (PBS), and then resuspending the pellet in two-packedcell volumes of RIPA buffer. Protein concentrations were determined using a modification of the Bradford method (Bio-Rad Laboratory). Steady state levels of total erbB2 and EGFR protein, as well activated erbB2 and EGFR were assessed by immunoprecipitation (IP) and Western blot. For IP Western blots, equivalent amounts of protein were precleared with Protein G Plus/Protein A agarose overnight at 48C. Precleared lysates were then incubated overnight at 48C with specific antibodies. Immune complexes were precipitated with Protein G Plus/Protein A agarose beads, washed in RIPA buffer and then boiled in sample loading buffer. Steady state levels of total Erk1/2 and activated Erk1/ 2 (p-Erk) as well as total AKT protein and activated AKT (p-AKT) protein were assessed by Western blot. For Western blot, equal amounts of proteins or immunoprecipitated target proteins were resolved by either 7.5% or 4 -15% gradient SDS polyacrylamide gel electrophoresis under reducing conditions. Proteins were transferred to Immobilon-P or nitrocellulose membranes. Efficiency and equal loading of proteins were evaluated by Ponceau S staining. Membranes were blocked for 1 h in TBS (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2.7 mM KCl) containing 4% (w/v) lowfat milk or 3% BSA (w/v). Membranes were then probed with specific antibodies recognizing target proteins. Proteins were visualized with the SuperSignal West Femto Maximum sensitivity substrate kit (Pierce).
Tumor xenografts
HN5 cells were grown in DMEM supplemented with 10% fetal bovine serum, sodium pyruvate and L-glutamine at 378C in a 95/5% air/CO 2 atmosphere. Cells grown in vitro were harvested in log phase and resuspended in PBS/Matrigel (1 : 1). Cells (2610 6 /mouse) in 0.2 ml were injected into the right flank of CD-1 nude mice. Female CD-1 nude mice were acquired from Charles River Laboratories. Mice were maintained in filter-topped cages in an aseptic environment with laminar flow filtered ventilation. Once tumor implants were palpable, mice were administered orally either vehicle (0.5% hydroxypropylmethylcellulose/0.1% Tween 80) alone or five doses of GW572016 at 10, 30, or 100 mg/kg given twice daily at 6 h intervals. Tumors were biopsied pretreatment and 4 h after the last dose. All animal surgery was conducted under aseptic conditions. For the initial biopsy, mice were anesthetized with isofluorane inhalation. The skin over the tumor was disinfected with iodine. A small hemostat was used to tease away the skin from the tumor, and scissors were used to make a 1 cm incision over the tumor. A scalpel and forceps were used to remove approximately 100 mg of tumor. The tumor was then frozen in liquid nitrogen. Wound clips were used to close the incision. The anesthetized mice were kept warm until they recovered mobility, usually less than 1 -2 min. For the terminal biopsy, mice were euthanized with CO 2 inhalation, and the remainder of the tumor excised and frozen in liquid nitrogen. Cell extracts were prepared by homogenization in RIPA buffer at 48C. BT474 tumors are maintained by serial passage of fragments into female C.B-17 SCID mice, for up to 10 passages. When tumor implants become palpable, mice were administered either vehicle (0.5% hydroxypropylmethylcellulose/0.1% Tween 80) alone or five doses of GW572016 at 100 mg/kg given twice daily at 12 h intervals by oral gavage. BT474 tumors were removed after the fifth dose of GW572016 after mice were euthanized with CO 2 inhalation. Cell extracts were prepared by homogenization as described for HN5 xenografts.
